GLP1R and metabolic syndrome: Taken together, with the overlap between OA risk factors and the metabolic syndrome, the demonstrated anti-inflammatory activities of GLP-1 in several tissues [10] and the expression of GLP-1R in joint tissues, GLP-1 analogues may be good therapeutic candidates for treating OA.